The botanical and chemical basics
Kratom (Mitragyna speciosa)
Kratom is the dried leaf of a tree in the Rubiaceae family — the same plant family as coffee. Its primary psychoactive compounds are alkaloids, principally mitragynine (60–70% of total alkaloid content) and 7-hydroxymitragynine (under 2% in natural leaf). Mitragynine is a partial agonist at mu-opioid receptors and also active at adrenergic and serotonin receptors. See our alkaloid guide for the chemistry.
Cannabis (Cannabis sativa) and THC
Cannabis is a flowering plant in the Cannabaceae family. Its primary psychoactive compound is delta-9-tetrahydrocannabinol (THC), a cannabinoid that binds the body's CB1 and CB2 cannabinoid receptors. THC effects include euphoria, altered perception, increased appetite, and at higher doses anxiety and impaired cognition.
Delta-8 THC
Delta-8 is a chemical isomer of delta-9 THC — the same molecular formula but a different position of one chemical bond. It occurs naturally in cannabis at very low concentrations. Most commercial delta-8 is produced by acid-catalyzed conversion from CBD, which became commercially viable after the 2018 Farm Bill made hemp-derived CBD legal. Delta-8 effects are qualitatively similar to delta-9 but commonly reported as milder.
Hemp-derived delta-9
After 2018, products containing delta-9 THC at concentrations under 0.3% by dry weight became federally legal as hemp products. By using high-volume gummies or edibles, manufacturers fit psychoactive doses of delta-9 into products that technically meet the 0.3% threshold by total weight. This is the regulatory loophole behind much of the "hemp-derived THC" market.
The pharmacology — they are not similar
Side by side at the receptor level:
- Kratom: mu-opioid partial agonist, alpha-2 adrenergic agonist, 5-HT receptor activity, dopamine release at higher doses
- THC (delta-8 or delta-9): CB1 and CB2 cannabinoid receptor partial agonist, with downstream effects on dopamine, glutamate, GABA, and endocannabinoid signaling
Different receptors. Different second-messenger pathways. Different neurological consequences. The user-facing experience can be superficially overlapping at certain doses (relaxation, mood elevation), but the mechanism is entirely different, and that difference matters for: tolerance dynamics, withdrawal profile, drug interactions, contraindications, and appropriate use contexts.
The effects — qualitative differences
Kratom
- Low dose: stimulation, focus, mood elevation
- Higher dose: relaxation, analgesia, sedation
- Dose-dependent shift from stimulant to sedative
- Effect duration: 4–6 hours
- Minimal cognitive impairment at typical doses
THC (delta-9 or delta-8)
- Euphoria, altered perception, time distortion
- Cognitive impairment proportional to dose
- Increased appetite
- Acute anxiety or paranoia possible, especially at higher doses
- Effect duration: 2–4 hours (smoked), 4–8 hours (edibles)
The risk profiles — also different
Kratom risks
- Dependence with daily use — real and meaningful, with withdrawal symptoms on cessation. See our tolerance and dependence guide.
- Cardiovascular load — heart rate and blood pressure increases at stimulant doses
- Drug interactions — particularly with other sedatives, opioids, benzodiazepines, and certain medications metabolized by liver enzymes
- Synthetic 7-OH products — the highest-risk subcategory, banned by KCPA-style laws. See our synthetic 7-OH explainer.
THC risks
- Acute anxiety, paranoia, panic — particularly at high doses or with high-THC flower
- Impaired driving and cognition for hours after use
- Cannabinoid hyperemesis syndrome with chronic heavy use
- Cognitive and motivational impacts with chronic adolescent use (most concerning population)
- Cannabis use disorder in roughly 9% of users (and ~17% of adolescent-onset users), per CDC data
- Acute psychosis risk in vulnerable individuals or with very-high- potency products
Comparison table
(Best understood with the caveats above; this is a quick reference, not a substitute for the detail.)
- Plant family: Kratom — Rubiaceae | THC — Cannabaceae
- Active compound: Kratom — mitragynine + 7-OH | THC — delta-9 or delta-8 THC
- Receptor target: Kratom — mu-opioid, adrenergic | THC — cannabinoid CB1/CB2
- Federal legality (US): Kratom — legal | Delta-9 — Schedule I; hemp-derived delta-9 under 0.3% legal | Delta-8 — gray area
- Tolerance speed: Kratom — fast (1–4 weeks daily) | THC — moderate (weeks to months daily)
- Withdrawal: Kratom — physical, opioid-like | THC — psychological + mild physical
- Cognitive impairment: Kratom — minimal at typical doses | THC — substantial
- Driving safe?: Both — no, neither is safe to drive on
The legal picture in brief
Kratom is federally legal in the United States and regulated state by state — most states permit it; a handful prohibit it. See our legality guide for the current map.
Delta-9 THC from cannabis is federally Schedule I, with state-level medical and recreational programs operating under federal enforcement discretion. Delta-9 from hemp under 0.3% by dry weight is federally legal under the 2018 Farm Bill, but many states have moved to restrict it independently.
Delta-8 is in active legal flux — federally legal under one reading of the Farm Bill, but more than 20 states have specifically restricted or banned it.
The legal frameworks evolved separately and don't reflect a coherent comparative judgment about either substance.
The combination question
Mixing kratom and THC is poorly studied. What's known: the combination produces additive sedation, can amplify cardiovascular effects, and increases cognitive impairment. Practical guidance if you choose to combine them despite these unknowns:
- Very low doses of each, never anywhere near typical recreational doses
- Never while driving or operating equipment
- Never with alcohol added on top
- Not as a regular pattern
- Not in combination with prescription medications without a physician's input
The honest bottom line
Kratom and THC are different plants, different molecules, different receptor systems, different effects, different risks, and different appropriate use cases. They share a retail shelf and a regulatory conversation, not a pharmacology. Treating them as the same general category — "alternative wellness" or "natural psychoactives" — is the kind of mental shortcut that produces bad consumer decisions. Pick one based on what you actually want and what you can responsibly manage; don't substitute one for the other based on a vague sense that they're similar.